阿托伐他汀强化疗法对高血压并发ST段抬高急性心肌梗死患者心脏功能与Lp-PLA2影响的研究

发布时间：2018-02-06 06:37

本文关键词： 阿托伐他汀高血压 ST段抬高心肌梗死 Lp-PLA　出处：《重庆医学》2016年36期 　论文类型：期刊论文

【摘要】：目的探讨阿托伐他汀强化疗法对高血压并发ST段抬高急性心肌梗死患者心脏功能与脂蛋白磷脂酶A2(LpPLA2)的影响。方法选取2014年6月至2016年4月该院收治的高血压并发ST段抬高急性心肌梗死患者78例,依据随机数表法分为观察组(阿托伐他汀强化疗法)和对照组(常规治疗),比较两组患者治疗前后的血压、血脂、Lp-PLA2、心功能变化。结果治疗前,两组患者的血压、血脂指标差异无统计学意义(P0.05);治疗后,两组患者的收缩压(SBP)、舒张压(DBP)、低密度脂蛋白胆固醇(LDL-C)明显降低,高密度脂蛋白胆固醇(HDL-C)显著升高,且观察组患者的SBP、HDL-C、LDL-C与对照组比较差异有统计学意义(P0.05)。治疗前,两组患者的Lp-PLA2差异无统计学意义(P0.05);治疗后,两组患者的Lp-PLA2均明显降低,且观察组变化幅度更大(P0.05)。治疗前,两组患者的心功能指标差异无统计学意义(P0.05);治疗后,观察组患者的左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)明显降低,左室射血分数(LVEF)、一氧化碳(CO)、心脏指数(CI)显著升高,与对照组比较差异有统计学意义(P0.05)。结论阿托伐他汀强化疗法能够明显降低高血压并发ST段抬高急性心肌梗死患者血压及Lp-PLA2水平,改善患者心脏功能,值得临床推广。
[Abstract]:Objective to investigate the effects of Atto vastatin intensive therapy on cardiac function and lipoprotein phospholipase A _ 2 (LpPLA _ 2) in patients with hypertension complicated with ST-segment elevation acute myocardial infarction (St segment elevation). Methods from June 2014 to April 2016, 78 patients with hypertension complicated with ST-segment elevation acute myocardial infarction were selected. According to the random table method, the patients were divided into two groups: observation group (Atto vastatin intensive therapy) and control group (routine treatment). The blood pressure, blood lipid and Lp-PLA2 were compared between the two groups before and after treatment. Results there was no significant difference in blood pressure and blood lipids between the two groups before treatment. After treatment, the systolic blood pressure (SBP), diastolic blood pressure (DBP), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) were significantly decreased in both groups. Compared with the control group, there was a significant difference between the observation group and the control group (P 0.05) before treatment. There was no significant difference in Lp-PLA2 between the two groups (P 0.05). After treatment, the Lp-PLA2 of the two groups was significantly decreased, and the change of the observation group was greater than that of the control group (P 0.05). Before treatment, there was no significant difference in cardiac function between the two groups (P 0.05). After treatment, left ventricular end-diastolic diameter (LVEDDN) and left ventricular end-systolic diameter (LVESD) were significantly decreased, left ventricular ejection fraction (LVEF) and carbon monoxide (CO) were significantly decreased in the observation group. Cardiac index (CI) increased significantly. Conclusion Atto vastatin intensive therapy can significantly reduce blood pressure and Lp-PLA2 levels in patients with hypertension complicated with ST-segment elevation acute myocardial infarction. Improving the heart function of patients is worth popularizing in clinic.
【作者单位】：郑州大学附属医院南阳市中心医院西药科;
【分类号】：R542.22;R544.1

【相似文献】